Atopic Dermatitis
FDA clears investigational new drug application for Zabalafin Hydrogel
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has been cleared by the FDA, Alphyn Biologics announced in a press release.
Connection between skin disease, heart health ushers in ‘holistic’ era of dermatology
In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.
Nemluvio approved in EU, UK, Switzerland for atopic dermatitis, prurigo nodularis
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.
Rezpegaldesleukin gets FDA fast track designation for atopic dermatitis
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate to severe atopic dermatitis that topical therapies have not adequately controlled, according to a press release.
Self-guided behavioral therapy as impactful as clinician-guided in atopic dermatitis
Self-guided cognitive behavioral therapy was non-inferior in reducing atopic dermatitis symptom severity as clinician-guided cognitive behavioral therapy, according to a study.
VIDEO: JAK inhibitors in dermatology effective, ‘safer than we could have ever hoped for’
MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.
Healio to cover latest in medical, aesthetic dermatology at South Beach Symposium 2025
Healio Dermatology will be reporting live at South Beach Symposium 2025 from Feb. 6 to 8 in Miami Beach, Florida. The 23rd annual event will deliver the latest updates in medical and aesthetic dermatology from top experts in the field.
Latine patients with psoriasis report unique cultural, ethnic experiences in US
Published results showed “Latine” patients with psoriasis in the U.S. have unique experiences with their disease and subsequent care, including lack of awareness about psoriasis, workplace difficulties and a preference for biologic treatment.
Ruxolitinib cream 1.5% effective, safe for greater AD surface area in pediatric patients
Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.
Top in allergy/asthma: ‘Psychosocial burden’ of food allergy; peanut allergy patch
Regardless of sociodemographic or clinical characteristics, children with food allergy face a significant psychosocial burden, according to a survey of caregivers published in The Journal of Allergy and Clinical Immunology: In Practice.